Home > Boards > US Listed > Biotechs > Protagonist Therapeutics Inc (PTGX)

$PTGX - For those wondering why it tanked today:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 585
Posts 25,924
Boards Moderated 2
Alias Born 11/16/07
160x600 placeholder
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera PR Newswire (US) - 10/21/2020 7:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 10/2/2020 5:14:48 PM
Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020 PR Newswire (US) - 9/17/2020 4:30:00 PM
Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire (US) - 9/15/2020 4:48:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/11/2020 4:33:39 PM
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference PR Newswire (US) - 9/10/2020 4:30:00 PM
Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar PR Newswire (US) - 9/2/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/18/2020 5:34:10 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/18/2020 5:05:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2020 4:35:09 PM
Protagonist Appoints Sarah O'Dowd to Board of Directors PR Newswire (US) - 8/13/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/12/2020 5:39:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 4:09:34 PM
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update PR Newswire (US) - 8/6/2020 4:01:00 PM
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera PR Newswire (US) - 6/17/2020 11:07:00 PM
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference PR Newswire (US) - 6/16/2020 6:05:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/9/2020 4:33:59 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/8/2020 4:05:46 PM
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress PR Newswire (US) - 6/4/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:21:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:20:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:19:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:17:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:16:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 6:13:03 PM
KarinCA Member Level  Monday, 03/26/18 09:17:18 PM
Re: None
Post # of 28 
$PTGX - For those wondering why it tanked today:

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
https://www.prnewswire.com/news-releases/protagonist-therapeutics-discontinues-phase-2b-propel-trial-of-ptg-100-for-the-treatment-of-ulcerative-colitis-following-interim-analysis-300619191.html
Quote:
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC). This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing 240 patient trial who had completed the 12 week treatment with PTG-100. Using pre-specified criteria, the DMC deemed the trial to be futile based on an analysis of the primary endpoint of clinical remission. No safety concerns were noted in the analysis.





To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences